Explore Video

Treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC)

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.

View comprehensive coverage of Breast Cancer from ESMO 2022

ASH 2022 - Update on Myelodysplastic Syndromes

Gradient Based Model based on 10 routinely used parameters (Age, Gender, Hb, WBC, MCV, Platelets, Neutrophils, Monocytes, Glucose, Creatinine) is now available to facilitate non-invasive diagnosis of MDS.

EHA Updates AML : QuANTUM phase 3 study showed significant overall survival in adults having FLT3-ITD+ acute myeloid leukaemia with  addition of quizartinib to standard induction and consolidation therapy alone.

Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.

Wherever possible all patients with prostate cancer should undergo both germinal and somatic BRCA mutation testing as they represent predictive biomarkers of greater sensitivity to treatment with PARP inhibitors.

In this video, Dr. Floege talks about the supportive evidence available and guideline recommendations on the preferred use of non-calcium phosphate binders.